Tuesday, May 27, 2014

ADC Development Using SMARTag Technology

As an emerging class of biologics, bioconjugates show great potential to not only improve existing therapeutics, but to create entirely new methods of treatment as well.  Anitbody Drug Conjugates (ADCs) are an important subset of these bioconjugate compounds but they do, however, come with a series of limitations.  Catalent recently published a whitepaper outlining some of the ways to overcome these shortcomings.  One of the authors of this study, David Rabuka, PhD, was able to further break down the restrictions of current ADC technology as well as provide us with some added insight on SMARTag technology. 

What’s the biggest implication you see of SMARTag technology?

I really like the idea of control over molecular architecture.  Approaching bioconjugation in a controlled and thoughtful process.  An analogy I like that I have heard more and more is a structure activity relationship (SAR) approach to generating bioconjugates.

What would be the benefit of this SAR approach to generating bioconjugates?

When doing medicinal chemistry on a small molecule for example, one approaches optimizing the compound by making systematic chemical changes to the molecule to see how those slight changes affect the biological properties of the potential drug.  Having an approach or a technology that allows one to do this in the context of bioconjugation has until recently not been possible.  Now it is (using technologies such as the SMARTag) and it opens up possibilities for optimization and understanding of ADCs that were previously inaccessible.

You talk about some of the limitations of current ADC technologies. How close are those to being addressed?

I think a number of the issues are being rapidly addressed while a few of the limitations are still a little behind.  I think the concept of site-specificity and dealing with heterogeneous mixtures is playing out in a number of different groups with one compound already in the clinic.  I think linker design and some of the more chemical elements (including new payloads) of an ADC are not as far along.

What’s one thing readers of this paper should take away?

That novel approaches to bioconjugate generation can provide simple paths to optimized biotherapeutics and next generation ADCs.

You can download the full whitepaper from Catalent here.

Want more on the latest in bioconjugate research? Check out Bioconjugates: From Targets to Therapeutics, June 4-6, San Francisco, CA.  You can download the brochure here.

SAVE 20%*. Register here and use code D141998BLOG.

Join us on LinkedIn
Follow us on Twitter
Check us out on Facebook

More on the latest in ADCs- ADCs: Where is There Room for Improvement?

*Off the standard rate. New registrants only.  

Share this article with your social network, just click below to share now!

No comments :

Post a Comment